Glaxo Relenza Program Will Address Diskhaler Ease of Use, Drug Efficacy

Glaxo plans to monitor patient experience with its Relenza Diskhaler through an "active" Phase IV program for the inhaled antiviral influenza treatment. FDA approved Relenza July 27.